Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.

Clinical Trial Description

This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of XmAb27564 in normal healthy volunteers. XmAb27564 is an engineered IL-2 mutein being developed for autoimmune diseases. ;

Study Design

NCT number NCT04857866
Study type Interventional
Source Xencor, Inc.
Contact Ralph Zitnik, MD
Phone 650-996-5321
Email [email protected]
Status Recruiting
Phase Phase 1
Start date April 19, 2021
Completion date June 30, 2022